Cargando…
The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis
PURPOSE: To evaluate the incidence risk of programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitor-related alopecia for cancer patients, the meta-analysis was put into practice. METHOD: The meta-analysis was designed and put into practice according to the preferred reporting it...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571948/ https://www.ncbi.nlm.nih.gov/pubmed/33080690 http://dx.doi.org/10.1097/MD.0000000000022555 |
_version_ | 1783597248246972416 |
---|---|
author | Li, Mingkai Huang, Linlin Ren, Xiuhong Liu, Lixia Shi, Qinghong Liu, Ling Wang, Xiao Tian, Yuan Yu, Lili Mi, Fuli |
author_facet | Li, Mingkai Huang, Linlin Ren, Xiuhong Liu, Lixia Shi, Qinghong Liu, Ling Wang, Xiao Tian, Yuan Yu, Lili Mi, Fuli |
author_sort | Li, Mingkai |
collection | PubMed |
description | PURPOSE: To evaluate the incidence risk of programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitor-related alopecia for cancer patients, the meta-analysis was put into practice. METHOD: The meta-analysis was designed and put into practice according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. RESULTS: After rigorous screening and verification, 22 clinical trials involving PD-1/PD-L1 inhibitors were collected for the final comprehensive analysis. The incidence risk of alopecia for all-grade in the PD-1/PD-L1 group was significantly lower than that in the control chemotherapy group (odds ratio [OR] = 0.01, 95% confidence interval [CI]: [0.01, 0.04], I(2) = 86%, Z = 8.73 [P < .00001]). Similar to the above, the incidence risk of alopecia for grade 3–5 related to PD-1/PD-L1 was obvious lower than the control group (OR = 0.17, 95% CI:[0.05, 0.55], I(2) = 0%, Z = 2.97 [P = .003]). When 7 clinical trials (PD-1/PD-L1 + Chemotherapy vs Chemotherapy) were taken to evaluate the risk of alopecia for all-grade and grade 3–5, no statistically significant results were found. CONCLUSION: The incidence risk of alopecia caused by PD-1/PD-L1 is significantly lower than chemotherapy, and there is no statistical significant evidence that PD-1/PD-L1 combined with chemotherapy would increase the incidence risk of alopecia. |
format | Online Article Text |
id | pubmed-7571948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-75719482020-10-29 The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis Li, Mingkai Huang, Linlin Ren, Xiuhong Liu, Lixia Shi, Qinghong Liu, Ling Wang, Xiao Tian, Yuan Yu, Lili Mi, Fuli Medicine (Baltimore) 5700 PURPOSE: To evaluate the incidence risk of programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitor-related alopecia for cancer patients, the meta-analysis was put into practice. METHOD: The meta-analysis was designed and put into practice according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. RESULTS: After rigorous screening and verification, 22 clinical trials involving PD-1/PD-L1 inhibitors were collected for the final comprehensive analysis. The incidence risk of alopecia for all-grade in the PD-1/PD-L1 group was significantly lower than that in the control chemotherapy group (odds ratio [OR] = 0.01, 95% confidence interval [CI]: [0.01, 0.04], I(2) = 86%, Z = 8.73 [P < .00001]). Similar to the above, the incidence risk of alopecia for grade 3–5 related to PD-1/PD-L1 was obvious lower than the control group (OR = 0.17, 95% CI:[0.05, 0.55], I(2) = 0%, Z = 2.97 [P = .003]). When 7 clinical trials (PD-1/PD-L1 + Chemotherapy vs Chemotherapy) were taken to evaluate the risk of alopecia for all-grade and grade 3–5, no statistically significant results were found. CONCLUSION: The incidence risk of alopecia caused by PD-1/PD-L1 is significantly lower than chemotherapy, and there is no statistical significant evidence that PD-1/PD-L1 combined with chemotherapy would increase the incidence risk of alopecia. Lippincott Williams & Wilkins 2020-10-16 /pmc/articles/PMC7571948/ /pubmed/33080690 http://dx.doi.org/10.1097/MD.0000000000022555 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 5700 Li, Mingkai Huang, Linlin Ren, Xiuhong Liu, Lixia Shi, Qinghong Liu, Ling Wang, Xiao Tian, Yuan Yu, Lili Mi, Fuli The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis |
title | The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis |
title_full | The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis |
title_fullStr | The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis |
title_full_unstemmed | The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis |
title_short | The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis |
title_sort | incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: a systematic review and meta-analysis |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571948/ https://www.ncbi.nlm.nih.gov/pubmed/33080690 http://dx.doi.org/10.1097/MD.0000000000022555 |
work_keys_str_mv | AT limingkai theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT huanglinlin theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT renxiuhong theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT liulixia theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT shiqinghong theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT liuling theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT wangxiao theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT tianyuan theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT yulili theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT mifuli theincidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT limingkai incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT huanglinlin incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT renxiuhong incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT liulixia incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT shiqinghong incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT liuling incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT wangxiao incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT tianyuan incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT yulili incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis AT mifuli incidenceriskofprogrammedcelldeath1programmedcelldeathligand1inhibitorrelatedalopeciaforcancerpatientsasystematicreviewandmetaanalysis |